{
  "docId": "019de071-41d7-735b-bdce-76898f0847d2",
  "docSlug": "eaafde7daeccaea38d88b7264ade91c5",
  "documentTitle": "Erasca | IPO Presentation Deck | 46 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 46,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-41d7-735b-bdce-76898f0847d2/16",
  "deckHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2",
  "deckJsonHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2.json",
  "deckAnchorHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "In multiple assays, ERAS-007 had longer target residence time vs. other ERKi's, which may allow for longer intervals between doses in patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "078d5a7d-cb38-46c3-96a2-119e291678ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.94,
        "x": 0.03,
        "y": 0.338
      },
      "kind": "table",
      "text": "Compound, k_off (s^-1), Residence Time (min); ERAS-007, 0.30 x 10^-4, 550; Ulixertinib, 10.1 x 10^-4, 16; Ravoxertinib, 13.9 x 10^-4, 12",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71946b3a-e72a-452f-ba83-06f94323f83f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "ERAS-007's uniquely long target residence time may enable dosing flexibility",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c36dd5db-bad1-414c-8d31-ec6d0a0a0407",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "6037d5de-dab6-419a-8798-a95461db9a79",
      "evidence": "table/data: Compound, k_off (s^-1), Residence Time (min); ERAS-007, 0.30 x 10^-4, 550; Ulixertinib, 10.1 x 10^-4, 16; Ravoxertinib, 13.9 x 10^-4, 12",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}